Clinical Trial Update: The Early Reversibility of Rocuronium After Different Doses of Neostigmine [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating how quickly rocuronium-induced paralysis reverses after varying doses of neostigmine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paralysis

Drugs mentioned

• Neostigmine (neostigmine)
• Rocuronium (rocuronium bromide)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Paralysis | Phase 4 | Status: COMPLETED